Quanterix Corporation (QTRX)
| Market Cap | 163.93M -30.7% |
| Revenue (ttm) | 144.98M +6.8% |
| Net Income | -104.19M |
| EPS | -2.33 |
| Shares Out | 47.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 414,179 |
| Open | 3.520 |
| Previous Close | 3.520 |
| Day's Range | 3.335 - 3.540 |
| 52-Week Range | 2.395 - 8.770 |
| Beta | 1.07 |
| Analysts | Hold |
| Price Target | 4.33 (+24.43%) |
| Earnings Date | Aug 7, 2026 |
About QTRX
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company’s products include assays include all components required to run enzyme-based immunoassay, s... [Read more]
Financial Performance
In 2025, Quanterix's revenue was $138.90 million, an increase of 1.07% compared to the previous year's $137.42 million. Losses were -$107.15 million, 178.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for QTRX stock is "Hold." The 12-month stock price target is $4.33, which is an increase of 24.43% from the latest price.
News
Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Anthem Blue Cross, Blue Shield establish commercial coverage for LucentAD
The company “announced a series of milestones that significantly advance the clinical adoption of blood-based Alzheimer’s testing. Together, these milestones reinforce the growing role of LucentAD(R) ...
Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced a series of milestones that significantly advance the clinical ...
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diag...
Quanterix Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is advancing its diagnostics strategy with a five-marker Alzheimer's test, aiming for FDA approval and strong payer support in the second half. Investments in commercial capabilities, innovation, and leadership are expected to drive growth and margin expansion, with cash flow breakeven targeted by year-end.
Quanterix appoints Faessler as Chief Financial Officer
Quanterix (QTRX) announced the appointment of Jason Faessler as the Company’s new Chief Financial Officer, effective June 22. Faessler joins Quanterix from Bruker Corporation (BRKR), where he served a...
Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the ap...
Quanterix appoints Geoff Albrecht as general manager, Diagnostics
Quanterix Corporation (QTRX) announced the appointment of Geoff Albrecht as Senior Vice President and General Manager of Diagnostics. Starting with Alzheimer’s Disease Diagnostics, Albrecht will lead ...
Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the ap...
Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that s...
Quanterix announces CFO transition
Quanterix (QTRX) “announced that Vandana Sriram, its CFO will depart the Company. A search for her successor is ongoing, and Ms. Sriram will continue as CFO through June 15, 2026,…
Quanterix Announces Planned Transition of Chief Financial Officer
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that V...
Quanterix Proxy statement: Proxy filing
Quanterix filed a proxy statement on May 8, 2026, providing details for shareholder voting and corporate governance matters.
Quanterix price target lowered to $4 from $7 at TD Cowen
TD Cowen lowered the firm’s price target on Quanterix (QTRX) to $4 from $7 and keeps a Hold rating on the shares. The firm said 1Q was largely in line…
Lucent Diagnostics announces collaboration with Tempus AI
Lucent Diagnostics, a brand of Quanterix Corporation (QTRX), announced a collaboration with Tempus AI (TEM) to broaden access to a novel blood-based biomarker panel designed to improve detection accur...
Quanterix reports Q1 EPS (37c), consensus (62c)
Reports Q1 revenue $36.4M, consensus $36.84M. The company said, “”We continue to make progress toward achieving cash flow breakeven as we move into a phase of growth now that we…
Quanterix affirms 2026 revenue outlook $169M-$174M
The company said, “Quanterix (QTRX) is reaffirming its guidance for 2026. The Company expects revenues of $169 to $174 million, which assumes no underlying improvement in the academic or pharmaceutica...
Quanterix Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 20% year-over-year to $36.4 million, with strong diagnostics partner growth but declines in core segments. Strategic investments in commercial effectiveness and diagnostics are expected to drive a stronger second half, with cash flow breakeven targeted by year-end.
Quanterix Slides: Q1 2026
Quanterix has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Quanterix Earnings release: Q1 2026
Quanterix released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Quanterix Quarterly report: Q1 2026
Quanterix has published its Q1 2026 quarterly earnings report on May 6, 2026.
Quanterix Releases Financial Results for the First Quarter of 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financ...
Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows
BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading ...
Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that i...
Quanterix Proxy statement: Proxy filing
Quanterix filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.